Table 1.

Completed CD30-Directed CAR-T Cell Clinical Trials for Patients with Relapsed/Refractory CD30+ Lymphoma

Trial	Wang et al.	Ramos et al.
Costimulatory Domain	4-1BB	CD28
Viral Vector	Lentivirus	Gammaretrovirus
Conditioning Chemotherapy	FC, GMC, PC	None
Doses	1.1–2.1 × 107 CAR-T cells/kg	2 × 107, 1 × 108, 2 × 108 CAR-T/m2
Number of Patients Treated	18 patients (17 HL, 1 cutaneous ALCL)	9 patients (6 HL, 1 cutaneous ALCL, 1 systemic ALCL, 1 DLBCL evolved to HL)
Responses	ORR 39% (7 PR); 6 with SD	ORR 33% (2 CR, 1 continued CR); 3 with SD

FC fludarabine and cyclophosphamide, GMC gemcitabine, mustargen, cyclophosphamide, PC nab-paclictaxel and cyclophosphamide, HL Hodgkin lymphoma, ALCL anaplastic large cell lymphoma, DLBCL diffuse large B-cell lymphoma, ORR overall response rate, PR partial response, SD stable disease, CR complete response